enGene (ENGNW) Stock Analysis

What enGene does

EnGene Holdings Inc., through its enGene, Inc. subsidiary, is a clinical-stage biotechnology company dedicated to advancing genetic medicines. These innovative therapies are designed for targeted delivery to mucosal tissues and other bodily organs. Its foremost developmental asset, EG-70 (detalimogene voraplasmid), represents a non-viral immunotherapy. This treatment is specifically aimed at patients with non-muscle invasive bladder cancer, specifically the carcinoma-in-situ (CIS) subtype, who have shown no response to Bacillus Calmette-Guérin (BCG) therapy. Established in 2023, the firm's operations are based in Saint-Laurent, Canada.

Key metrics

ETFs linked to ENGNW

Broad-market and Healthcare sector ETFs an investor holding enGene is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ENGNW fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for enGene?

enGene trades under the ticker ENGNW on NASDAQ.

Which exchange is ENGNW listed on?

ENGNW is listed on NASDAQ.

What sector does enGene operate in?

enGene is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ENGNW in a portfolio?

PortView shows ENGNW's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.